Lipid regulation of mitochondria
Mitochondria are dynamic organelles that grow, divide and fuse in most of the human body’s cells; these dynamic membrane processes are critical for mitochondrial health.
Our laboratory studies mitochondrial division and fusion, focusing on three mechanochemical dynamin-related GTPases: Drp1, mitofusin and Opa1. Drp1 is a soluble GTPase that splits the mitochondrial membrane. Mitofusin and Opa1 are integral membrane GTPases that work together to fuse the mitochondrial membranes. Mutations in each of these enzymes lead to human diseases that mainly affect central and peripheral nervous systems.
Mitochondrial division and fusion need to be balanced to maintain functional mitochondrial size, structure and distribution within cells. This dynamic balance is controlled by several layers of mechanisms, including gene expression, post-translational modifications and protein degradation of these GTPases and their binding partners. In addition, mitochondrial phospholipids play important roles in regulation of mitochondrial dynamics.
Cardiolipin, or CL, in the mitochondrial outer membrane promotes oligomerization of Drp1 to drive mitochondrial division; CL in the inner membrane mediates fusion through heterotypic interactions with Opa1. Hiromi Sesaki et al.Drp1 interacts with two phospholipids, cardiolipin, or CL, and phosphatidic acid, or PA, in the mitochondrial outer membrane, or OM. CL is synthesized in the mitochondrial inner membrane, or IM, and a fraction of CL is transported to the OM. Drp1 is recruited to the mitochondria through its receptor proteins on the surface of mitochondria; binding to CL stimulates Drp1 to assemble into high-order oligomers that function as a division machinery. The machinery is regulated further by PA. Binding to PA restrains the assembled machinery from initiating the constriction of the mitochondrial membranes, likely creating a priming step for mitochondrial division. Binding sites for CL and PA are different in Drp1; therefore, these phospholipids may create different degrees of the regulation through a combination of single or concurrent binding to Drp1.
The production of CL and PA is a dynamic process in the OM. As described above, CL is transported to the OM from the IM. This transport may be regulated through dynamic interactions at the intramitochondrial OM-IM contact sites. In the OM, there is a phospholipase D, MitoPLD, which converts CL to PA. Since MitoPLD directly binds Drp1, conversion of stimulatory CL to inhibitory PA may happen locally in the vicinity of the division machinery. PA also is produced in the endoplasmic reticulum, or ER, and imported into the OM through ER-mitochondrial contact sites. Drp1 often divides mitochondria at these sites. Mitochondrial PA levels also may be regulated by this interorganellar interaction.
PA changes the mitochondrial membrane’s biophysical properties and facilitates mitofusion-mediated membrane fusion. Opa1, similar to Drp1, binds CL, and this interaction drives membrane fusion. Therefore, lipid transport and synthesis coupled to intramitochondrial contact site dynamics and interorganellar interactions play key roles in controlling mitochondrial dynamics.
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.
In the inaugural JBC Methods Madness Tournament, cryo–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% — a margin thinner than shaved ice.
Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.